Bailly Clément, Leforestier Rodolphe, Jamet Bastien, Carlier Thomas, Bourgeois Mickael, Guérard François, Touzeau Cyrille, Moreau Philippe, Chérel Michel, Kraeber-Bodéré Françoise, Bodet-Milin Caroline
Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France.
Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France.
Int J Mol Sci. 2017 Feb 18;18(2):445. doi: 10.3390/ijms18020445.
Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malignant plasma cells in the bone marrow. MM results in diffuse or focal bone infiltration and extramedullary lesions. Over the past two decades, advances have been made with regard to the diagnosis, staging, treatment, and imaging of MM. Computed tomography (CT) and magnetic resonance imaging (MRI) are currently recommended as the most effective imaging modalities at diagnostic. Yet, recent data from the literature suggest that positron emission tomography combined with computed tomography (PET/CT) using F-deoxyglucose (FDG) is a promising technique for initial staging and therapeutic monitoring in this pathology. This paper reviews the recent advances as well as the potential place of a more specific radiopharmaceutical in MM.
多发性骨髓瘤(MM)是一种血液系统肿瘤,其特征是骨髓中恶性浆细胞的克隆性增殖。MM导致弥漫性或局灶性骨浸润和髓外病变。在过去的二十年里,MM在诊断、分期、治疗和影像学方面都取得了进展。计算机断层扫描(CT)和磁共振成像(MRI)目前被推荐为诊断时最有效的成像方式。然而,最近文献数据表明,使用F-脱氧葡萄糖(FDG)的正电子发射断层扫描联合计算机断层扫描(PET/CT)是这种病理情况下初始分期和治疗监测的一种有前景的技术。本文综述了MM的最新进展以及一种更具特异性的放射性药物的潜在应用价值。